Dan has 36 years experience in the pharmaceutical industry including most recently 29 years with Pfizer. He began his career working on a wide variety of different drug product formulations including oral (tablets, capsules and suspensions), sterile injectables, ophthalmics and transdermals. Most recently he was Senior Research Director in the Pharmaceutical Sciences Department leading CMC teams for various small molecule projects from early to late stage. These teams spanned many disease areas including Cardiovascular/Metabolic Disease, Oncology, Infectious diseases, Neuroscience, Ophthalmology and Rare Diseases. He led the CMC teams for filing and approval of Geodon Oral Suspension, Vyndaqel, Ibrance and Paxlovid. Dan joined Antabio in 2026 where he is Head of CMC.
